Structure-Based Design of 4-(1-Methyl-1 H -indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors
Journal of Medicinal Chemistry · 12.03.2026 · 69 (5) · 5199-5218
DOI: 10.1021/acs.jmedchem.5c02552 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 06.02.2026. Verfasst von Wenjian Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecule…. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 3, Drug Design, Pyrimidines, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Program for Changjiang Scholars and Innovative Research Team in University, China Maurice Wilkins Centre Collaborative Research Program and Cancer Society Auckland Northland.
Abstract (Originalsprache)
Aberrant fibroblast growth factor receptor 3 (FGFR3) activation drives bladder carcinogenesis in humans, but currently approved pan-FGFR inhibitors lack FGFR3 isoform selectivity and fail to counter clinically acquired resistance mutations (e.g., FGFR3 V555M/L). Herein, we report the structure-based drug design of 4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine derivatives as the first covalent FGFR3 selective inhibitors. The representative compound 10s displayed high potency against FGFR3 (IC50 = 6.8 nM) and 5-60-fold selectivity over FGFR1/2/4. It was also effective against the common clinically acquired FGFR3V555M resistance mutation with an IC50 value of 19.2 nM. Furthermore, 10s exhibited strong antiproliferative effects in FGFR3-driven RT112/84 cells (IC50 = 9.2 nM). Structural characterization using MALDI-TOF-MS and X-ray crystallography confirmed covalent binding of 10s to FGFR3. Compound 10s also showed significant antitumor efficacy in the RT112/84 bladder cancer xenograft model, offering a promising compound to address both selectivity and resistance in FGFR3-targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, International Cooperative Laborat…
- Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs. Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
- Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
ORCID-Profile: Yongheng Chen, Xiaoyun Lu
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Program for Changjiang Scholars and Innovative Research Team in University
- China Maurice Wilkins Centre Collaborative Research Program and Cancer Society Auckland Northland
- Major Project of Guangzhou National Laboratory
Zitieren
APA
Zhu, W., Chen, X., Li, X., Lin, J., Lin, X., Liu, X., Deng, W., Song, X., Tu, Z., Patterson, A. V., Smaill, J. B., Chen, Y., & Lu, X. (2026). Structure-Based Design of 4-(1-Methyl-1 H -indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors. Journal of Medicinal Chemistry, 69(5), 5199-5218. https://doi.org/10.1021/acs.jmedchem.5c02552
Vancouver
Zhu W, Chen X, Li X, Lin J, Lin X, Liu X, et al. Structure-Based Design of 4-(1-Methyl-1 H -indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors. Journal of Medicinal Chemistry. 2026;69(5):5199-5218. doi:10.1021/acs.jmedchem.5c02552
BibTeX
@article{Zhu2026,
author = {Zhu, Wenjian and Chen, Xiaojuan and Li, Xiaofei and Lin, Jieying and Lin, Xiaojing and Liu, Xueru and Deng, Wuqing and Song, Xiaojuan and Tu, Zhengchao and Patterson, Adam V and Smaill, Jeff B and Chen, Yongheng and Lu, Xiaoyun},
title = {Structure-Based Design of 4-(1-Methyl-1 H -indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {5},
pages = {5199--5218},
doi = {10.1021/acs.jmedchem.5c02552}
}
EUVIMED